DOCSLIB.ORG

Effects of Fluorouracil and Fluorouridine on Protein Synthesis in Rabbit Retina

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Fluorouracil and Fluorouridine on Protein Synthesis in Rabbit Retina Investigative Ophthalmology & Visual Science, Vol. 31, No. 9, September 1990 Copyright © Association for Research in Vision and Ophthalmology Effects of Fluorouracil and Fluorouridine on Protein Synthesis in Rabbit Retina John A. Leon, James M. Dritt, Richard H. Hopp, Richard P. Mills, and Ann H. Milam 5-Fluorouracil (5-FU) and its active metabolite 5-fluorouridine (FUR) are currently being evaluated for the treatment of proliferative vitreoretinopathy and the control of scarring after glaucoma filtering procedures. To test for retinal toxicity, the authors examined the effect of intravitreal injections of 5-FU and FUR on protein synthesis in rabbit retinal photoreceptors and ganglion cells. In addition, the toxic effect of subconjunctival 5-FU injections, after a trephine filtering procedure, on ganglion cell protein synthesis was examined. Albino rabbit eyes were given either unilateral intravitreal injections of 1 mg of 5-FU, 2.5 mg of 5-FU, or 0.1 mg of FUR, or subconjunctival injections of 3 mg of 5-FU twice daily after a trephine procedure. Quantitative autoradiography was used to study ganglion cells and photoreceptor outer segment renewal, and scintillation counting was used to quantify newly synthesized protein transported axonally from ganglion cell bodies to the superior colliculus (SC). Marked reduction of labeled protein reaching the SC was noted after either intravitreal 0.1 mg of FUR (41% inhibition after a single injection and 53% after two injections) or 2.5 mg of 5-FU (41% after one injection and 26% after two injections). This reduction was still present after 8 days in eyes receiving 0.1 mg of FUR (32%) and 2.5 mg of 5-FU (22%). Quantitative autoradiography of retinal photorecep- tors and ganglion cells corroborated these data, demonstrating inhibition of outer segment renewal after one or two injections of either 0.1 mg of FUR or 2.5 mg of 5-FU. This inhibitory effect was statistically significant using the paired t-test for both drugs. No mean inhibition was observed after intravitreal 1 mg of 5-FU injections or after subconjunctival injections of 5-FU. Invest Ophthalmol Vis Sci 31:1709-1716, 1990 The drug 5-fluorouracil (5-FU) is potent antime- coma filtration procedures in animal models1' and in tabolite that inhibits intraocular fibroblast and retinal initial clinical studies.12"15 It is currently being evalu- pigment epithelium proliferation and contraction in ated in a multicenter clinical trial. animal models1"5 and in vitro.6"9 Currently 5-FU is The 5-FU alters DNA synthesis through inhibition under evaluation for treatment of proliferative vit- of the enzyme thymidylate synthetase and decreases reoretinopathy (PVR), and it was found to signifi- RNA function secondary to incorporation of 5-FU cantly reduce the incidence of traction retinal de- metabolites into newly synthesized RNA.16 The anti- tachment (TRD) produced by injection of cultured proliferative and anticontractile effects of 5-FU are fibroblasts into the vitreous chamber of animal eyes. probably due to production of altered RNA.17 Fluo- A dose of 1 mg of 5-FU injected intravitreally re- rouridine (FUR) is the key 5-FU metabolite that af- duced TRD in nonvitrectomized rabbit eyes.1'2'5 fects RNA synthesis and is up to 100 times more Multiple intravitreal injections of 0.5 mg of 5-FU effective than 5-FU in inhibiting fibroblast prolifera- into vitrectomized rabbit eyes have also been effica- tion in vitro.18 cious against PVR.3 A pilot study on patients with Toxicity of 5-FU and FUR has been assessed by PVR demonstrated a moderate success rate of 65% use of light and electron microscopy and by electro- for retinal reattachment after intravitreal 5-FU.10 physiology. We evaluated retinal toxicity of intravit- When applied topically or injected subconjunctivally, real and subconjunctival injection of 5-FU and FUR 5-FU also inhibits postoperative scarring after glau- in rabbits. Since ganglion cells and photoreceptors have high rates of protein synthesis, we measured the From the Department of Ophthalmology, University of Wash- effects of these drugs on protein synthesis and axonal ington School of Medicine, Seattle, Washington. transport in retinal ganglion cells and on outer seg- Supported in part by NIH Grants EY01730 and EY01311; the Lewis Berkowitz Family, National Retinitis Pigmentosa and ment (OS) renewal in photoreceptors. Chatlos Foundations; and in part by an award from Research to Prevent Blindness, Inc. (R.P.B.). A.H.M. is a Senior Scholar of Materials and Methods R.P.B. Reprint requests to Richard P. Mills, MD, Department of Oph- Fifty-three albino rabbits (2-3 kg) were used for thalmology RJ-10, University of Washington, Seattle, WA 98195. this study. This study was conducted in accordance 1709 Downloaded from iovs.arvojournals.org on 09/28/2021 1710 INVESTIGATIVE OPHTHALMOLOGY 6 VISUAL SCIENCE / September 1990 Vol. 31 with the ARVO Resolution on the Use of Animals in poral to the optic disc. Inhibition of protein synthesis Research. The eyes of 24 rabbits were anesthetized in ganglion cells was determined by comparing topically with proparacaine 0.5%, and the right eyes counts from a drug-treated eye with the companion (OD) received two intravitreal injections 24 hrs apart control eye injected with saline.21 of 1.0 mg of 5-FU, 2.5 mg of 5-FU, or 0.1 mg of FUR, diluted in 0.1 ml of 0.9% saline, doses previously Outer Segment Renewal in Photoreceptors thought to be nontoxic to rabbit or primate ret- 101819 inas. The needle tip was positioned just anterior Quantitative autoradiography was also used to as- 20 to the optic disc in the manner of Orcutt et al. A sess effects of 5-FU and FUR on protein synthesis in second group of seven rabbits underwent a bilateral retinal photoreceptors. Rod outer segment (ROS) re- Elliot trephine filtering procedure after sedation with newal occurs continuously, reflecting a high level of intramuscular ketamine and Rompun. A 1.0-mm protein synthesis in the rod inner segment and inser- trephine was used, straddling the limbus, followed by tion of newly synthesized protein as a band in the conjunctival coverage with a fornix-based flap. These ROS.22 Fifteen rabbits from the first group and 22 rabbits received subconjunctival injections OD of 3 rabbits from the third group were anesthetized with mg of 5-FU in 0.3 ml of 0.9% saline 180° from the sodium thiopental and perfused intravascularly with surgery wound. These injections were repeated twice 4% paraformaldehyde and 0.5% glutaraldehyde in daily for 7 days, according to the method of Gressel et 0.13 M phosphate buffer 72 hrs after intravitreal in- al," using intramuscular ketamine and Rompun for jection of 3H-leucine. The eyes were immediately anesthesia. Left eyes served as controls in all rabbits enucleated and immersed in the fixative for 24 hr. and received equivalent volumes of saline injected The anterior third of each eye was removed, and the intravitreally or subconjunctivally. Twenty-four retina was sectioned and processed as described hours after the last drug or saline injection, all eyes above for autoradiography. Autoradiographic grains 3 were injected intravitreally with 150 ^Ci H-leucine were counted per unit area of radioactive ROS band (New England Nuclear). A third group of 22 rabbits in a standardized segment of retina, just temporal to received only one injection of 2.5 mg of 5-FU or 0.1 the optic disc, to determine if photoreceptor protein mg of FUR into the midvitreous cavity OD under synthesis, as evidenced by OS renewal, had been af- ophthalmoscopic control. Again, the left eye served fected by prior drug treatment. as a control and received an equivalent volume of saline injected intravitreally. After drug exposure times of 1 day for 10 rabbits and 8 days for 12 rabbits, Protein Synthesis In all eyes were injected intravitreally with 3H-leucine. All rabbits showing evidence of leakage from the in- Ganglion Cells 30 jection site were excluded from the study. 21.8 i Protein Synthesis in Ganglion Cells 20-: 17.5 1 Quantitative light microscopic autoradiography 10- was used to determine the effects of 5-FU and FUR 21 1 on protein synthesis in ganglion cells of the retina. ^ 3 Four hours after intravitreal injection of H-leucine, C nine rabbits from the first group were killed with an -10- overdose of sodium thiopental; the eyes were imme- C <D 1 -14.8 diately removed and fixed in 4% paraformaldehyde 2 -20 i in 0.13 M phosphate buffer for 72 hr. Samples of a> retina with underlying choroid and sclera were em- -30- bedded in methacrylate (Sorvall). Sections 2.5 nm in thickness were processed for autoradiography, in- -40 cluding standardized dipping in photographic emul- 1.0mg. 5-FU 2.5mg. 5-FU 0.1 mg. FUR sion, exposure of all slides for 24 hr, and simulta- Drug Tested neous photographic processing. The slides were then dried and stained with Richardson's methylene blue- Fig. 1. Inhibitory effects of 5-FU and FUR on protein synthesis azure II mixture. Autoradiographic grains were in ganglion cells of the rabbit retina. Mild inhibition was found after two intravitreal injections of 2.5 mg 5-FU and 0.1 mg FUR. counted per unit cytoplasm of ganglion cells from a No reduction was found after intravitreal injection of 1.0 mg 5-FU. standardized segment of the retina immediately tem- The vertical bars represent means ± SEM. Downloaded from iovs.arvojournals.org on 09/28/2021 No. 9 5-FU AND FUR IN RABBIT RETINA / Leon er ol 1711 Fig. 2. Photomicrographs of rabbit retinas demon- strating incorporation of 3H-leucine into ganglion cell protein (originals X800).
Load more

Recommended publications
  • ASHP Guidelines on Handling Hazardous Drugs
    132 Drug Distribution and Control: Preparation and Handling–Guidelines ASHP Guidelines on Handling Hazardous Drugs ASHP published its first guidance on hazardous drugs (HDs) Because newer studies have shown that contamination in 1983 as part of the 1983–84 ASHP Practice Spotlight: Safe is widespread in healthcare settings and that more workers Handling of Cytotoxic Drugs.1,2 This was followed by tech- than previously thought are exposed, these guidelines should nical assistance bulletins in 1985 and 1990 and the ASHP be implemented wherever HDs are received, stored, pre- Guidelines on Handling Hazardous Drugs in 2006.3-5 The pared, transported, administered, or disposed.8-11 2006 guidelines were created to harmonize with the National Comprehensive reviews of the literature covering an- Institute for Occupational Safety and Health (NIOSH) Alert: ecdotal and case reports of surface contamination, worker ex- 6,9,12 Preventing Occupational Exposure to Antineoplastic and posure, and risk assessment are available from NIOSH, Other Hazardous Drugs in Health Care Settings issued in the Occupational Safety and Health Administration 13,14 15-20 2004.6 The ASHP 2006 HD guidelines were current to 2005. (OSHA), and individual authors. The primary goal In 2007, the United States Pharmacopeial Convention of this document is to provide recommendations for the safe revised United States Pharmacopeia (USP) chapter 797 handling of HDs. These guidelines represent the research (Pharmaceutical Compounding—Sterile Preparations)7 to and recommendations of many groups and individuals who harmonize with the NIOSH 2004 Alert. It became effective have worked tirelessly over decades to reduce the potential May 1, 2008, establishing many of the NIOSH recommenda harmful effects of HDs on healthcare workers.
    [Show full text]
  • NOV 1 72010 1.0 Submitter
    510(k) SUMMARY NOV 1 72010 1.0 Submitter Name Shen Wei (USA) Inc. Street Address 33278 Central Ave., Suite 102 Union City, CA. 94587 Phone No. (510)429-8692 Fax No. (510)487-5347 Date of Summary Prepared: 08/12/10 Prepared by: Albert Li 2.0 Name of the device: Glove Proprietary or Trade Name: Blue and Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs Common Name: Exam gloves Classification Name: Patient examination glove, Specialty Chemotherapy'(per 21 CFR 880.6250 product code LZC) Classification Information: Class I Nitrile patient examination glove 8OLZC, powder-free and meeting all the requirements of ASTM D 631 9-O0a-05 and is tested with chemotherapy drugs according to ASTM D 6978-05. 3.0 Identification of the Legally Marketed Device: Blue and Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera Regulatory Class I Nitrile patient examination Product code: 8OLZA 5 10(k): K092411 4.0 Description of the Device: Blue and Red with Pearlescent® Pigment, Powder Free Nitrite Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs meets all the requirements of ASTM D 6978-05, ASTM D63 19-00a(2005) and FDA 21 CFT 880.6250. 5.0 Intended Use of Device: Product: Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs A disposable device intended for medical purpose that is worn on the examiner's hand to prevent contamination between patient and examiner. This device is single use only.
    [Show full text]
  • Wear the Battle Gear That Protects Against 52 Chemotherapy Drugs!
    YOU’RE FIGHTING CANCER. Wear the Battle Gear That Protects Against 52 Chemotherapy Drugs! PURPLE NITRILE-XTRA* Gloves and HALYARD* Procedure Gowns for Chemotherapy Use have been tested It’s 52 vs. You. for resistance to 52 chemotherapy drugs.† Arsenic Trioxide (1 mg/ml) Cyclophosphamide (20 mg/ml) Fludarabine (25 mg/ml) Mitomycin (0.5 mg/ml) Temsirolimus (25 mg/ml) Azacitidine (Vidaza) (25 mg/ml) Cytarabine HCl (100 mg/ml) Fluorouracil (50 mg/ml) Mitoxantrone (2 mg/ml) Trastuzumab (21 mg/ml) Bendamustine (5 mg/ml) Cytovene (10 mg/ml) Fulvestrant (50 mg/ml) Oxaliplatin (2 mg/ml) ThioTEPA (10 mg/ml) Bleomycin Sulfate (15 mg/ml) Dacarbazine (10 mg/ml) Gemcitabine (38 mg/ml) Paclitaxel (6 mg/ml) Topotecan HCl (1 mg/ml) Bortezomib (Velcade) (1 mg/ml) Daunorubicin HCl (5 mg/ml) Idarubicin (1 mg/ml) Paraplatin (10 mg/ml) Triclosan (1 mg/ml) Busulfan (6 mg/ml) Decitabine (5 mg/ml) Ifosfamide (50 mg/ml) Pemetrexed (25 mg/ml) Trisenox (0.1 mg/ml) Carboplatin (10 mg/ml) Docetaxel (10 mg/ml) Irinotecan (20 mg/ml) Pertuzumab (30 mg/ml) Vincrinstine Sulfate (1 mg/ml) Carfilzomib (2 mg/ml) Doxorubicin HCl (2 mg/ml) Mechlorethamine HCl (1 mg/ml) Raltitrexed (0.5 mg/ml) Vinblastine (1 mg/ml) Carmustine (3.3 mg/ml)† Ellence (2 mg/ml) Melphalan (5 mg/ml) Retrovir (10 mg/ml) Vinorelbine (10 mg/ml) Cetuximab (Erbitux) (2 mg/ml) Eribulin Mesylate (0.5 mg/ml) Methotrexate (25 mg/ml) Rituximab (10 mg/ml) Zoledronic Acid (0.8 mg/ml) Cisplatin (1 mg/ml) Etoposide (20 mg/ml) † Testing measured no breakthrough at the Standard Breakthrough Rate of 0.1ug/cm2/minute, up to 240 minutes for gloves and 480 minutes for gowns, except for carmustine.
    [Show full text]
  • 1 Contents of Online Supporting Information Etable 1. Study
    Contents of Online Supporting Information eTable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone eTable 2. Study characteristics of head to head trials of intravesical therapy eTable 3. Study characteristics of trials comparing dose or duration of a single drug eTable 4. Summary of the evidence eFigure 1. Literature flow diagram eFigure 2. Meta-analysis of doxorubicin versus no intravesical therapy: Risk of recurrence eFigure 3. Meta-analysis of epirubicin versus no intravesical therapy: Risk of recurrence References for the Supplement 1 eTable 1. Study characteristics for trials of intravesical therapy vs. TURBT alone Author, Year Risk of Bias Inclusion Criteria Population Characteristics Intervention Followup Duration Abrams, 19811 Histologically confirmed All characteristics reported for A: Doxorubicin, 50 mg (in 50 6 months for all patients. High superficial bladder tumor; all randomized patients, not mL saline). Single instillation, Recurrent only, with presence the groups analyzed: within 24 hours of TURBT of tumors at both of two Age, mean (years): 72 vs. 68 (n=30). previous endoscopies 12 Male: 70% vs. 79% months and 6 months before Recurrent bladder cancer: B: No adjuvant treatment. entry into trial; Stages Ta or 100% vs. 100% TURBT alone (n=30). T1; Included grades not Ta: 73% vs. 77% specified, but "well" and T1: 27% vs. 23%; "moderate" differentiation included. Akaza, 19872 Histologically proven Age, mean (years): 62.3 vs. A: Doxorubicin, 30 mg (in 30 Maximum (years): 5; Not [Study One] superficial bladder cancer 62.9 vs. 62.9 vs. 62.9 mL saline). Total 8 instillations: reported as median/mean, nor (followup of Niijima, (primary or recurrent).
    [Show full text]
  • The Cost Burden of Blood Cancer Care a Longitudinal Analysis of Commercially Insured Patients Diagnosed with Blood Cancer
    MILLIMAN RESEARCH REPORT The cost burden of blood cancer care A longitudinal analysis of commercially insured patients diagnosed with blood cancer October 2018 Gabriela Dieguez, FSA, MAAA Christine Ferro, CHFP David Rotter, PhD Commissioned by The Leukemia & Lymphoma Society Table of Contents EXECUTIVE SUMMARY ............................................................................................................................................... 2 BACKGROUND ............................................................................................................................................................. 1 FINDINGS ...................................................................................................................................................................... 2 PREVALENCE AND COST OF BLOOD CANCER BY AGE GROUP ....................................................................... 2 INCIDENCE OF BLOOD CANCER ........................................................................................................................... 4 BLOOD CANCER CARE SPENDING FOLLOWING INITIAL DIAGNOSIS ............................................................... 5 PATIENT OUT-OF-POCKET COSTS FOLLOWING A BLOOD CANCER DIAGNOSIS ........................................... 9 The impact of insurance plan design on patient OOP costs .......................................................................... 10 CONSIDERATIONS FOR PAYERS ...........................................................................................................................
    [Show full text]
  • Thiotepa Stable in Light and in Acidic Solution, but Stable in Alkaline Solutions (IARC 1990)
    Report on Carcinogens, Fourteenth Edition For Table of Contents, see home page: http://ntp.niehs.nih.gov/go/roc Thiotepa stable in light and in acidic solution, but stable in alkaline solutions (IARC 1990). Physical and chemical properties of thiotepa are listed CAS No. 52-24-4 in the following table. Known to be a human carcinogen Property Information a First listed in the Second Annual Report on Carcinogens (1981) Molecular weight 189.2 Melting point 51.5°Ca Also known as tris(1-aziridinyl)phosphine sulfide b Log Kow 0.53 Water solubility 190 g/L at 25°Cb Vapor pressure 0.00845 mm Hg at 25°Cb N Sources: aHSDB 2009, bChemIDplus 2009. NNP Use S Carcinogenicity Thiotepa suppresses cell growth and division and was introduced in 1953 for use in cancer chemotherapy to treat lymphoma and a vari- Thiotepa is known to be a human carcinogen based on sufficient ev- ety of solid and soft-tissue tumors. It was commonly used in cancer idence from studies in humans. Thiotepa was first listed in the Sec- therapy until the early 1970s (only 3 kg of thiotepa was used in 1973). ond Annual Report on Carcinogens in 1981 as reasonably anticipated Although thiotepa has largely been replaced by the nitrogen mustards, to be a human carcinogen based on sufficient evidence of carcinoge- it still has specific uses, particularly as a component of experimen- nicity from studies in experimental animals and insufficient evidence tal high-dose chemotherapy regimens. Thiotepa was most effective of carcinogenicity from studies in humans. Thiotepa was reclassified in treating adenocarcinoma of the breast, ovary, and bladder, malig- as known to be a human carcinogen in the Eighth Report on Carcin- nant lymphoma, bronchogenic carcinoma, and Wilms tumor.
    [Show full text]
  • All-Trans Retinoic Acid and Arsenic Trioxide Resistance of Acute Promyelocytic Leukemia with the Variant STAT5B-RARA Fusion Gene
    Letters to the Editor 1606 leukemia mouse model. This effect was proposed to be due, at REFERENCES least in part, to inhibition of FBXW7, a negative regulator of Notch 1 Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. Gene 8 signaling. However, FBXW7 targets the degradation of other expression signatures define novel oncogenic pathways in T cell acute lympho- oncogenic proteins, such as c-Myc and mTOR, and the expression blastic leukemia. Cancer Cell 2002; 1: 75–87. of miR-223 is significantly elevated in TAL1-positive T-ALL cases 2 Cardoso BA, de Almeida SF, Laranjeira AB, Carmo-Fonseca M, Yunes JA, (Supplementary Figure 2), suggesting that the oncogenic function Coffer PJ et al. TAL1/SCL is downregulated upon histone deacetylase of this microRNA may extend beyond mere collaboration in Notch- inhibition in T-cell acute lymphoblastic leukemia cells. Leukemia 2011; 25: induced leukemia. Moreover, the proleukemic role of mir-223 may 1578–1586. 3 O’Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/SCL induces leukemia be also achieved by downregulating targets such as E2F1, FOXO1, by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 2004; 5: RHOB or EPB41L3, which have been associated with induction of 587–596. apoptosis and/or have tumor-suppressive roles (Supplementary 4 Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A et al. Table 5). Interestingly, the intriguing possibility that miR-223 may Core transcriptional regulatory circuit controlled by the TAL1 complex potentially act downstream of TAL1 to negatively regulate MEF2C, in human T cell acute lymphoblastic leukemia.
    [Show full text]
  • Systematic Review and Individual Patient Data Meta-Analysis Of
    EUROPEAN UROLOGY 69 (2016) 231–244 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority – Guidelines Editorial by J. Alfred Witjes on pp. 245–246 of this issue Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Richard J. Sylvester a,*, Willem Oosterlinck b, Sten Holmang c, Matthew R. Sydes d, Alison Birtle e, Sigurdur Gudjonsson f, Cosimo De Nunzio g, Kikuo Okamura h, Eero Kaasinen i, Eduardo Solsona j, Bedeir Ali-El-Dein k, Can Ali Tatar l, Brant A. Inman m, James N’Dow n, Jorg R. Oddens o, Marek Babjuk p a EORTC Headquarters, Department of Biostatistics, Brussels, Belgium; b Ghent University Hospital, Department of Urology, Ghent, Belgium; c University of Gothenburg, Department of Urology, Gothenburg, Sweden; d Medical Research Council Clinical Trials Unit at University College London, Department of Cancer and Other Non-Infectious Diseases, London, UK; e Royal Preston Hospital, Rosemere Cancer Centre, Preston, UK; f Skane University Hospital, Department of Urology, Malmo, Sweden; g Ospedale Sant’Andrea, University ‘‘La Sapienza,’’ Department of Urology, Rome, Italy; h Higashi Nagoya Hospital, Department of Urology, Nagoya, Japan; i Hyvinkaa Hospital, Department of Urology, Hyvinkaa, Finland; j Valencia Oncology Institute, Department
    [Show full text]
  • Thiotepa, Busulfan and Cyclophosphamide As a Preparative Regimen for Allogeneic Transplantation for Advanced Chronic Myelogenous Leukemia
    Bone Marrow Transplantation, (1999) 23, 977–981 1999 Stockton Press All rights reserved 0268–3369/99 $12.00 http://www.stockton-press.co.uk/bmt Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia D Przepiorka1, I Khouri1, P Thall2, R Mehra1, M-S Lee3, C Ippoliti1, S Giralt1, J Gajewski1, K van Besien1, B Andersson1,MKo¨rbling1, AB Deisseroth1 and R Champlin1 Departments of 1Blood and Marrow Transplantation, 2Biomathematics and 3Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Summary: blast crisis and 15–40% for transplantation in accelerated or second chronic phase.1–7 Busulfan-based preparative Thirty-six adults with chronic myelogenous leukemia regimens have been favored by some for CML as a result (CML) in second or greater chronic phase, accelerated of the potent anti-myeloid activity and ease of adminis- phase, or blast crisis underwent marrow or blood stem tration of busulfan, and results with the busulfan–cyclopho- cell transplantation from an HLA-matched sibling using sphamide regimen are similar to those achieved with cyclo- high-dose thiotepa, busulfan and cyclophosphamide phosphamide and total body irradiation for patients with (TBC) as the preparative regimen. All evaluable advanced CML.8 N,NЈ,NЈ-triethylenethiophosphoramide patients engrafted and had complete donor chimerism. (thiotepa) is a highly myelosuppressive alkylating agent One patient failed to clear meningeal leukemia, and one that lacks overlapping toxicities with busulfan or cyclopho- patient had one of 30 metaphases positive for the Phila- sphamide.9 We evaluated the combination of thiotepa with delphia chromosome at 2 months post transplant.
    [Show full text]
  • North Carolina Medicaid Division of Health Benefits Abbreviated
    North Carolina Medicaid Division of Health Benefits Abbreviated Physician Administered Drug Program Catalog •Unless otherwise indicated, the catalog contains procedure codes representing drugs, biologics, devices and vaccines which are only covered for FDA approved indications. •11 digit National Drug Codes (NDCs) are required to be billed along with their corresponding procedure code. Drugs and biologics must be classified as CMS covered outpatient drugs from a labeler/manufacturer participating in the Medicaid Drug Rebate Program (MDRP). •Procedure codes for covered devices and vaccines are not required to be from a rebating labeler/manufacturer as they are not classified as covered outpatient drugs. HCPCS HCPCS Code Description Brand Name Generic Name Code 90291 Cytomegalovirus immune globulin (CMV-IgIV), human, for intravenous use Cytogam® cytomegalovirus immune globulin intravenous, human 90371 Hepatitis B Immune Globulin (Hbig), human, for intramuscular use HyperHep, Nabi-HB hepatitis b immune globulin (human) rabies immune globulin, (human) treated with solvent/detergent, for infiltration and intramuscular 90375 Rabies Immune Globulin (RIg), human, for intramuscular and/or subcutaneous use HyperRAB® S/D, HyperRAB® administration rabies immune globulin, (human) solution for infiltration and intramuscular injection Rabies Immune Globulin, heat-treated (RIg-HT), human, for intramuscular and/or 90376 Imogam® Rabies-HT rabies immune globulin (human), heat treated subcutaneous use 90389 Tetanus Immune Globulin (TIg), human, for intramuscular
    [Show full text]
  • Inflammatory High-Risk Breast Cancer
    Bone Marrow Transplantation (2000) 26, 51–59 2000 Macmillan Publishers Ltd All rights reserved 0268–3369/00 $15.00 www.nature.com/bmt High-dose busulfan, melphalan and thiotepa as consolidation for non- inflammatory high-risk breast cancer F Gutierrez-Delgado, LA Holmberg, H Hooper, FR Appelbaum, RB Livingston, RT Maziarz, P Weiden, S Rivkin, P Montgomery, K Kawahara and W Bensinger Fred Hutchinson Cancer Research, University of Washington and Puget Sound Oncology Consortium, Seattle, WA, USA Summary: disease,3–7 and stage III disease8,9 have a probability of disease-free survival (DFS) at 5 years of 13 to 45% which The purpose of this study was to evaluate the toxicity falls to 10 to 30% at 10 years. and efficacy of high-dose busulfan, melphalan and thi- The experimental and clinical observations suggesting a otepa (Bu/Mel/TT) in patients with high-risk non- significant dose–response relationship in metastatic and pri- inflammatory breast cancer defined as stage II disease mary breast cancer10–14 have encouraged the evaluation of у10 lymph nodes (n = 52) or stage III (n = 69), and high-dose chemotherapy supported with autologous stem prognostic factors for treatment outcome. One hundred cell infusion (HDC/ASCI) as treatment for breast cancer. and twenty-one patients (median age, 46 years) were While a wide range of regimens and trials have evaluated treated with high-dose Bu (12 mg/kg), Mel (100 mg/m2) this approach in metastatic disease, relatively few trials and TT (500 mg/m2) (HDC) followed by autologous stem have investigated the therapeutic potential of HDC/ASCI cell infusion (ASCI).
    [Show full text]
  • Brand Generic Guide
    Table Of Contents Section 1 .................................................2-6 Introduction Section 2 ................................................7-14 Dr. Reddy’s Product Portfolio Section 3 ............................................. 15-52 Generic Names To Brand Names Section 4 ......................................... 53-90 Brand Names To Generic Names Section 5 ..........................................91-110 Clinical Resources 1 Dear Healthcare Professional, At Dr. Reddy’s North American Generics, we strive every day to do what matters most to patients –accelerating access to the affordable medicines they need, because Good Health Can't Wait. Each of us is driven by the urgency for good health and committed to providing you with the most affordable products at the best value every day. The medicines we provide to patients and our customers are among the more than 1000 products listed in the Dr. Reddy’s Brand-to-Generic-to-Brand Conversion Guide. The complimentary pocket guide features an easy-to-use conversion guide and other clinical resources to assist you with conversions, calculations, assessments and more. It includes: • Generic-to-Brand Conversion Guide An alphabetical listing of generic products, cross-referenced to the corresponding brand names • Brand-to-Generic Conversion Guide An alphabetical listing of brand products, cross-referenced to the corresponding generic names • Clinical Resource Section Resources such as charts on liver function assessment, equi-analgesic doses, and high-alert drugs • Product Portfolio The complete Dr. Reddy’s product portfolio is presented in Section 2 of the guide. Throughout the guide, Dr. Reddy’s products are printed in color. As the Brand-to-Generic-to-Brand Conversion Guide earns 1 its place as a valuable tool in your clinical setting, know that all of us at Dr.
    [Show full text]